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Summary 
 
Polycystic kidney disease is the most common genetic, 
life-threatening disease, affecting more than 12.5 million 
people worldwide. Fluid-filled renal cysts that eventually 
destroy renal tissue and renal function altogether are 
characteristic of polycystic kidney disease.  The 
autosomal dominant form of the disease which is also 
the most common form, ADPKD, is linked to mutations 
in the genes PKD1 and PKD2.  The complete normal 
function of PKD1 and PKD2 is unknown, but most 
research suggests that they play some role in cell 
signaling and controlling the cell cycle. The diseased 
phenotype is thought to be caused by mutations in 
these genes that cause misregulation of the cell cycle 
leading to proliferation. The recessive form of polycystic 
kidney disease, ARPKD, is triggered by a mutation in the 
gene PKHD1 and is manifested more severely than the 
dominant form.  ARPKD has not been as widely studied 
as ADPKD because it affects fewer people than the 
dominant form of the disease.  Currently, there is no 
treatment for any of the forms of PKD, though some 
studies have shown some promise in effectively 
attenuating renal cystic growth.  
 
History, Basic Facts, and Epidemiology 
 
Polycystic kidney disease (PKD) was first documented 
around 1540. It was known as Bright’s disease until the mid 
1980’s when it acquired its current name. It is the most 
common genetic life-threatening disease, affecting 1 out of 
1000 people, 600,000 Americans, and 12.5 million people 
worldwide. 
There are two forms of PKD: autosomal dominant 
PKD (ADPKD) and autosomal recessive PKD (ARPKD). The 
genes responsible for ADPKD are PKD1 and PKD2, and the 
mean age of onset is between 30 and 40 years of age. The 
disease infects men, women, and all races equally. 
PKHD1 gene causes the recessive form of PKD 
(ARPKD). This type of the disease is the more aggressive 
and lethal form. The mean age of onset is during prenatal 
development. Similarly to ADPKD, all genders and race are 
equally affected. Most infected individuals of ARPKD, 
depending on disease severity, die by their early twenties. 
Patients with ADPKD or ARPKD die as a result of the 
disease, but medicine may be taken to relieve pain and to 
prolong life. 
 
Symptoms 
 
PKD is characterized by the formation of cysts on the 
kidneys. Cysts are blister-like structures that enlarge over 
time and fill with fluid.  The proliferation of cysts on the 
kidneys impairs proper kidney function. The major symptoms 
of PKD stem from poor kidney function. High blood pressure 
is an early symptom of polycystic kidney disease.  Other 
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symptoms include blood in the urine, urinary tract infections, 
kidney stones, and dehydration.  As the disease progresses, 
other major health problems can arise.  Mitral valve 
prolapse, which is characterized by the inability of the mitral 
valve of the heart to close all the way, can lead to chest pain 
and heart palpitations.  Intracranial aneurisms, or the 
bursting of blood vessels in the brain, may also occur in PKD 
patients.  Cysts can eventually spread to the liver.  These 
cysts do not impair the function of the liver, but can be 
painful for the patient.  
 
PKD1 and 2 as causes of polycystic kidney disease 
 
Renal cystogenesis is caused by rapidly proliferating 
epithelial cells in kidney ducts and tubules. Attempts to 
elucidate the molecular mechanism of the disease have 
focused on PKD1 and PKD2 mutations, which result in 
grossly increased cell proliferation due to an acceleration of 
the cell cycle. Polycystins-1 and 2 (PC1 and PC2), the 
proteins coded for by PKD1 and PKD2, respectively, are 
membrane-bound proteins. Researchers have found that the 
cell-regulatory functions of these proteins are due to the 
effects they have on other regulatory pathways. How PKD1 
and PKD2 interact with these pathways and which pathways 
they interact with are the two central questions of most 
ADPKD research.  
 
The Normal PKD1 gene and polycystin-1 
 
The majority of PKD research has focused on the PKD1 
gene, because mutations involving it account for 85% of all 
cases of ADPKD. Located on chromosome 16, this gene 
encodes polycystin-1 (PC1). The complete function of the 
gene and its protein product is unknown; but an 
understanding of PKD1 has begun to take shape as 
researchers discover more about it. 
Using computer analysis, Martijn, et al. (2000) 
found that PC1 is a large transmembrane protein containing 
an extracellular N-terminus and an intracellular C-terminus. 
The C-terminal region has multiple hydrophobic domains 
(Bhunia, et al., 2002). Polycystin-1 anchorage to adhesion 
complexes is needed for signal transduction in order to 
maintain cell adhesion protein sorting and cell polarity 
(Martijn, et al. 2000). 
The PKD1 gene is thought to be a member of the 
tumor suppressor family of genes. This is supported by 
Boletta, et al. (2000), who found that polycystin-1 expression 
resulted in reduced growth rates and spontaneous 
tubulogenesis in epithelial kidney cells. One downstream 
effect of PC1 activity might be the inhibition of apoptosis. 
Polycystin-1 decreases the proliferation of epithelial cells in 
developing tissues, allowing them to proceed down terminal 
differentiation pathways without undergoing apoptosis. 
(Boletta, et al. 2006).  
 
The diseased function of PKD1: two hypotheses 
 
Although a few of the pathways by which PKD1 regulates 
the cell cycle have been discovered, the exact nature of this 
regulation is still unknown. There are two conflicting 
hypotheses about how PC1 interacts with the regulatory 
pathways. The first suggests that PC1 controls many 
different regulatory pathways. Bhunia, et al. (2002) argue 
that mutations in PKD1 give the diseased phenotype 
because all of these pathways are disrupted as a result.  A 
disruption   to   only   one   or   two  tumor   suppressors,   for  
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Figure 1. Overview of the molecular causes of polycystic kidney disease.  PKD1 resides on chromosome 16 and encodes polycystin-1 (PC1). 
PKD2 encodes PC2 and PKHD encodes fibrocystin. These three proteins are thought to interact with other regulatory pathways in the cell. Mutations 
would then cause dis-regulation of the cell cycle and proliferation of kidney epithelial cells, resulting in cysts. A few specific pathways have been 
discovered, such as the JAK-STAT pathway and PC1’s interaction with p53, but there are thought to be other pathways that are affected by PC1 and 
PC2 (Low, et al., 2006). Fibrocystin is known to be cleaved (as is PC1) and translocated into the nucleus, but its precise function in the nucleus 
remains obscure. p53 and p21 are both tumor suppressors whose expression is partially regulated by PC1 or PC2. Question marks and dotted line 
indicate hypothesized pathways.  
 
example, does not cause cystogenesis, because there are 
many other regulatory pathways to compensate. These 
“back up” pathways remain properly regulated by PKD1 
(Bhunia, et al., 2002). This may explain why PKD is a 
genetic disease—there needs to be a basic problem that 
affects all of these regulatory pathways. 
The second hypothesis is that there must be a 
master pathway that is commonly affected by PKD1, PKD2, 
and all of the numerous other genes that give a PKD-like 
phenotype when mutated (Shillingford, et al., 2006). In 
support of this hypothesis, it is argued that all the nearly 
identical polycystic phenotypes must result from the 
disruption of a single, common pathway, and that all the 
genes that can cause this phenotype must necessarily be 
affecting this same pathway. For example, the ADPKD 
phenotype caused by PKD1 is virtually indistinguishable 
from that caused by PKD2. This strongly argues for a 
common target pathway for the protein products of both 
genes. Although they seem quite different, the “multiple-
pathways” hypothesis and the “common pathway” 
hypothesis do not necessarily contradict each other. 
 
Feedback Inhibition in the PKD1 gene, polycystin-1 and 
the tumor suppressor p53 
 
In seeming support of the multiple pathways hypothesis, 
PC1 has been implicated in many cell cycle control 
pathways. Van Bodegom, et al. (2006) found that the tumor 
suppressor protein p53 is a transcriptional repressor of 
PKD1. Kidneys of p53 null mice exhibited up regulated 
PKD1 mRNA levels compared to wild type mice, indicating 
that more polycystin-1 was being transcribed. Polycystin-1 
activates p53, which in turn controls PKD1 gene expression. 
This finding illustrates a type of feedback inhibition among 
PKD1, the protein it encodes, and p53, which represses 
PKD1. 
 
PKD1 expression arrests the cell cycle 
 
Another important discovery is that PKD1 expression 
induces accumulation of cells in the G0/G1 phase of the cell 
cycle. It seemed likely that this cell-cycle arrest was due to 
interaction with a tumor suppressor, but research was 
needed to establish this. In 2002, Bhunia, et al. discovered 
that over expression of PC1 resulting in increased 
downstream activity of p21, a Cdk inhibitor. They found that 
PC1 physically attaches, along with PC2, to JAK2, allowing 
JAK2 to phosphorylate STAT1, a transcription factor. 
STAT1, when phosphorylated, induces expression of p21, a 
tumor suppressor. So in this pathway, PKD1, along with 
PKD2, functions as a tumor suppressor, since it acts as the 
initiator of a signaling pathway that eventually leads to the 
expression of p21. 
This suggests a mechanism for the development 
of polycystic kidney disease. If a mutation in PKD1 reduced 
its ability to interact with JAK2, then an important tumor 
suppressor would be down-regulated in the cell, resulting in 
cell proliferation. In support of this, Bhunia, et al. (2002) 
found that the levels of phosphorylated STAT1 and p21 were 
much lower than in mice that had the PKD1 gene than in 
mice that did not. Mice lacking the PKD1 gene also 
developed cysts, while those having the gene did not. This 
study argues strongly for the common-pathway hypothesis. 
Both PC1 and PC2 are required to activate JAK2, so a 
mutation in either of them would disrupt the same pathway in 
nearly the same way. 
The above study may suggest that there are other 
nuances of the function of PC1. The implication is that PC1 
interacts with JAK2 at the membrane, and that STAT1 is 
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then phosphorylated before going to the nucleus to act as a 
transcription factor. There may be other ways PC1 can affect 
transcription in the nucleus. 
Qian, et al. (2002) showed that PC1 can be 
cleaved at the GPS domain on its extracellular N-terminus. 
They deleted various segments of the extracellular N-
terminus of PC1, expressed these in mammalian cell lines, 
and tested for cleavage. Cleavage only occurred if a specific 
domain, called the receptor for egg jelly (REJ) domain, was 
present. If this domain was missing in whole or in part then 
cleavage would not occur. 
Several mutations to the REJ domain, that occur 
in nature, were identified and expressed in mammalian cell 
lines. These engineered cells were then cultured in an in 
vitro tubulogenesis model, where they were found to develop 
cyst-like structures. Cells with wild-type PC1 developed 
tubules as normal (Qian, et al., 2002). Apparently, cells need 
PC1 to be cleaved at the GPS domain in order to function 
properly. 
 
Cleavage of PC1 is important for signaling 
 
The finding that PC1's extracellular N-terminus could be 
cleaved raised the question of whether the cytoplasmic 
terminus could also be cleaved. Could this be the 
mechanism by which PC1 regulates the cell cycle? In 2006, 
Low et al. showed PC1's cytoplasmic C-terminus tail 
undergoes cleavage and translocation to the nucleus. 
Interestingly, this study also found that PC1 interacts with a 
STAT protein. The C-terminal tail coprecipitated with STAT6 
and P100. STAT6 is a transcription factor that acts in concert 
with P100 to induce gene transcription. P100 and STAT6 
were also found to colocalize on the cilia of cells in culture, 
which further supports that they are closely associated with 
one another. Also, STAT6 dependent transcription was 
increased when the C-terminal tail of PC1 was present in the 
cell, but not when PC1 remained fully attached to the 
membrane. Additionally, the expression of the PC1 C-
terminal tail alone was found to cause cystogenesis in Zebra 
fish embryos (Low, et al., 2006). 
Low, et al (2006) also outlined a possible 
mechanism by which disruption or malfunction of this 
pathway could contribute to cystogenesis. Because PC1 is 
located primarily on the cilia of the epithelial cells, it has 
been widely hypothesized that the polycystins may play a 
role in mechanosensation (Delmas, 2004). Low, et al. (2006) 
tested the effect of flowing versus stagnant fluid on a culture 
of cells that expressed the full-length PC1 protein. They 
found that under flow conditions, STAT6 localized to the 
nucleus, but under no flow conditions, STAT6 remained 
localized on the cilia. If the PC1 C-terminus remained 
associated with STAT6, the no flow condition must have 
resulted in cleavage of this tail and subsequent translocation 
to the nucleus, where the complex would presumably 
increase gene transcription. Low, et al. (2006) suggest that 
cyst formation in kidney tubules may cause fluid flow to stop, 
cause cleavage of PC1 and up-regulation of STAT6-
dependent gene transcription. This could cause further cell 
proliferation, worsening the condition of the already diseased 
kidney. 
 
PKD2 gene and polycystin-1 
 
Although most cases of ADPKD are due to PKD1, about 
15% of all cases of ADPKD are caused by mutations in 
PKD2 (Wu, et al., 1998).  The gene PKD2 is located on 
chromosome 4 in the region 4q21-q23.  The complete 
function of the protein product of PKD2, polycystin-2 (PC2), 
is still unknown.  Recent studies have begun to uncover the 
properties of PC2.  This will provide insight into the 
mechanism of cyst formation that is caused by lack of PC2.  
How PKD2 is involved in the cell cycle is at the focus of 
research, since cyst formation is clearly caused by abnormal 
cell proliferation. Insight into the normal function of PC2 will 
allow the formation of possible hypotheses as to how cysts 
form on the kidneys as a result of PKD2 mutation. 
 
How PKD2 Mutations Cause Cyst Growth 
 
According to some studies, polycystin-2 has channel-like 
properties (Gonzalez-Perrett, et al., 2001).  It acts as a 
nonselective cation channel across an epithelial membrane.  
It is also a Ca
2+ 
permeable membrane.  PKD2 in some cases 
specifically regulates Ca
2+ 
transport in response to store 
depletion through interactions with specific TRPC proteins 
(Tsiokas, et al).  Abnormal function of this channel could 
cause excessive fluid buildup in renal cells, which results in 
renal cyst formation and eventual destruction of renal tissue.  
This presents a possible mechanism of cyst formation in 
ADPKD patients. 
Gallagher, et al. (1999) show that polycystin-2 
may also have a link with the actin cytoskeleton through its 
interaction with a protein Hax-1.  Hax-1 interacts with 
cortactin, an actin-binding protein.  The relationship between 
the three proteins suggests that PKD2 is involved in the 
formation of cell-matrix contacts.  In this case, cyst formation 
in PKD patients could be explained because of dysfunctional 
formation of cell-matrix contacts leading to cystic 
enlargement in the tubular structures in the kidney.  This 
proposes another mechanism for cyst formation in PKD 
patients with a mutation in PKD2.  However, the specific 
pathway in this protein complex is not clear.  There are a 
number of possible ways that the three proteins affect cell-
matrix interactions.  The correct pathway has yet to be found 
and may be the target of future studies. 
In order to suggest reasonable treatments for 
PKD, we must understand the disease completely.  Studies 
on PKD2 and its protein product, PC2, continue so that we 
may fill in this gap in knowledge in the hopes of finding a 
cure for this disease.  Studies that delve deeper into the 
findings of others to further the research will bring us closer 
to finding a cure for PKD.  For example, targeting the 
molecular pathway for the interaction between polysyctin-2, 
Hax-1, and cortactin will allow a better understanding of the 
normal function of polycystin-2 that is disrupted by mutation, 
causing cyst proliferation. 
 
Relationship between PKD1 and PKD2 
 
The fact that ADPKD is manifested the same way in patients 
with mutations in PKD1 and mutations in PKD2 supports the 
common pathway hypothesis, although this hypothesis 
remained unverified for several years. It is important to note 
that PC1 was not able to phosphorylate JAK2 without PC2. 
When PC2 was present with PC1, JAK2 was phosphorylated 
and p21 levels increased.  Therefore, the activity of PC1 
depends on the presence or absence of PC2.  This finding 
helps uncover the relationship between PKD1 and PKD2.  
Neither polycystin can activate the JAK-STAT pathway 
alone, which explains why a mutation in either gene causes 
abnormal cell proliferation of cystic epithelia.  
 
Location, Function, and Localization of PKHD1 
 
As more evidence is being found to support this interaction 
between PKD1 and PKD2, scientists are beginning to better 
understand the causes of ADPKD. However, as knowledge 
for ADPKD is advancing, research on ARPKD has only 
begun. Ward, et al. (2002), Onuchic, et al. (2002), and 
Zhang, et al. (2004) have just discovered the gene 
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responsible for PKHD1 in the 6p21cen-region on 
chromosome 6. Accordingly, this has opened research 
possibilities for researchers to discover the gene responsible 
for ARPKD, what protein PKHD1 encodes, and to ascertain 
what mutations cause ARPKD. Furthermore, researchers 
are postulating possible protein kidney functions.  
PKHD1, thus far, is known to encode a 4,074 
amino acid chain protein and is composed of 67 exons. The 
protein is known as fibrocystin and/or polyductin (Zhang, et 
al., 2004). It contains multiple TIG and TIG-like domains, 
TMEM2 and DKFZ homology, and a transmembrane 
domain. Fibrocystin colocalizes to the basal bodies of the 
primary cilia in the renal epithelia of the kidney and is an 
integral trans-membrane protein (Zhang, et al., 2004). Its 
current function is unknown, but Zhang, et al. (2004) and 
Hiseberger, et al. (2006) hypothesize that polyductin may 
initiate epithelial differentiation, alter ciliary function, or act as 
a receptor protein. Zhang, et al. (2004) have found that the 
expression of fibrocystin, in the mice PKHD1 ortholog, is 
essential during embryological organogenesis (Zhang, et al., 
2004). Fibrocystin lines the fetal epithelial cells of neural and 
mesonephric tubes, which eventually differentiate into 
collecting ducts.  
The protein is also expressed on human adult 
kidney ducts and tubules. Thus, it seems that the expression 
of PKHD1 is essential in development and for normal 
function of the kidney (Zhang, et al., 2004). 
 
Mutations in ARPKD 
 
To begin research on the particularities of ARPKD, 
researchers are establishing studies on known mutations of 
PKHD1. However, one difficulty hindering research on 
ARPKD is that mutations randomly span the chromosome. In 
addition, all mutations are “private mutations” unique to an 
individual (Bergmann, et. al., 2005). Hence, there can be an 
infinite amount of mutations with an infinite amount of 
causes. This also causes different phenotypes in individuals 
depending on the severity of the case. The symptoms can 
range from mild kidney dysfunctions to death. Moderate 
symptoms are generally associated with missense mutations 
while death correlates with termination-type mutations. Other 
mutations that have been discovered include insertion, 
deletion, frame-shift, and truncation (Rossetti, et al., 2003). 
Specific mutation cases and up-to-date information on 
ARPKD can be found in the ARPKD mutation database 
(URL: http://www.humgen.rwth-aachen.de). 
 
Fibrocystin Cleavage is Regulated by Ca
2+
  
 
Even with the difficulty of research by the numerous 
mutations of PKHD1, studies are still performed. Hiseberger, 
et al. (2006) elucidated a possible pathway for fibrocystin 
production through the ADPKD pathway including polycystin-
1 and 2. One known mechanism of polycystin-1 is that it 
undergoes regulated proteolytic cleavage at the C-terminus 
with the mediated release of Ca
2+
. Therefore, Hiesberger, et 
al. (2006) hypothesize that fibrocystin undergoes similar 
regulation by Ca
2+
, which, in turn, causes proteolytic 
cleavage at the C-terminus. It is nevertheless postulated that 
a mutation or an interference with this pathway may be a 
factor for PKD, but this theory has yet to be supported 
(Hiesberger, et al., 2006).  
Although PKHD1 was only recently discovered, 
researchers are already mapping the abundant mutations of 
PKHD1. This, however, is only the start, as scientists are 
beginning to elucidate fibrocystin function and its importance 
in the kidney. As research continues to enhance knowledge 
about ARPKD, as well as for ADPKD, the chances of finding 
a treatment also increase. For now, there are short-term 
treatments and clinical trials for potential drugs. 
 
 
 
Figure 2. Proteins involved in polycystic kidney disease. This diagram shows the autosomal dominant polycystic kidney disease (ADPKD) 
proteins, polycystin-1 and 2 and the autosomal recessive polycystic kidney disease (ARPKD) protein, fibrocystin. These models of the proteins 
structure demonstrate the cleavage sites, conserved domains and regions of homology with other proteins. The locations of N-terminus – in the 
extracellular space – and the C-terminus – in the cytosol - are shown for each protein.  
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Current treatment research 
 
Currently there is no effective therapy for ADPKD or ARPKD. 
Kidney transplantation and dialysis are the only methods that 
can be performed to prolong life. Murine models have been 
successfully employed to increase the understanding of the 
molecular mechanisms of polycystic kidney disease. These 
tests have been used to explore possible therapeutic 
techniques for polycystic kidney disease, mostly ADPKD, the 
more common form. Current treatments of polycystic kidney 
disease involve caspase inhibitors, CDK inhibitors, 
Triptolide, and mTOR inhibitors. 
 
Caspase inhibitors  
 
The caspase’s role in apoptosis makes it a suitable possible 
target for treatment of PKD. Caspase inhibition in other 
animal models has been successfully used on non-renal 
organs; heart, liver and pancreas, that have been injured 
due to apoptosis (Tao, et. al., 2005). IDN-8050, a caspase 
inhibitor, was used to treat Han:SPRD rats who had PKD. 
IDN-8050 significantly reduced apoptosis and cell 
proliferation in cystic and non-cystic tubules and attenuates 
the loss of kidney function. These treatments were shown to 
ameliorate the PKD, provide evidence that there were no 
detectable deleterious side effects to the mice, and an 
absence of renal tumors was observed (Tao, et. al., 2005). 
More testing should be conducted in the implementation of 
caspase inhibitors as treatments for humans with ADPKD 
since they are already being used to treat hepatic 
dysfunction and ischemia-perfusion in humans.  
 
CDK inhibitors 
 
Cyclin-dependent kinases (CDK) are used to regulate the 
cell cycle, transcription and mRNA processing. However, in 
PKD the dysregulation of this cell cycle has been thought to 
be the main reason behind the cystogenesis. (R)-
Roscovitine, a CDK inhibitor, has been successfully used to 
inhibit the cyst and kidney growth, and normalizes blood 
urea nitrogen (BUN) concentrations in jck and cpk mice, a 
murine model of rapidly progressive PKD (Bukanov, et. al., 
2006). Roscovitine was also observed to be active against 
cyst formation in multiple parts of the nephron.  Its selective 
inhibition of CDKs with minimum off-target kinase activities 
makes it a very viable clinical contender in ADPKD 
treatment, where cyst formation occurs in many multiple 
nephron segments of the kidney. Molecular studies on the 
cell cycle has also shown that Roscovitine is able to 
effectively arrest cell cycle, inhibit transcription, and, like the 
caspase inhibitors, attenuate apoptosis (Bukanov, et. al., 
2006).  
 
Vasopressin-2-receptor antagonists  
 
The vasopressin-2-receptor antagonist (V2RA), lowered 
renal cAMP and inhibited PKD development in the three 
animal models with similar phenotypes as human PKD 
(Torres, et. al., 2007). Tolvaptan, a potent and selective 
human V2RA, inhibits the development of PKD (Walz, 2006), 
significantly lowers the renal cAMP levels, kidney weights, 
cyst and fibrosis volumes. It is also known to induce mitosis 
and apoptosis and inhibits Ras and ERK activation (Torres, 
et. al., 2007). The renal selectivity of Tolvaptan on 
congestive heart failure and cirrhosis and its low side effect 
on animal models and patients with these diseases (Torres, 
et. al., 2007), makes it an attractive drug for ADPKD 
treatment. 
 
Triptolide 
 
Triptolide an active diterpene produced in plants found in Lei 
Gong Teng. A traditional Chinese medicine, it has been 
shown to induce apoptosis or arrest cell growth depending 
on concentrations used and cell type treated (Leuenroth, et. 
al., 2007).  Triptolide has been found to induce Ca
2+
 release 
by a Polycystin-2 dependent mechanism. In addtition, 
Triptolide arrests epithelial cell growth and attenuates cyst 
formation by restoring Ca
2+
 signaling (Leuenroth, et. al., 
2007). Thus, Triptolide offers a therapeutic solution of PKD 
through the restoration of calcium signaling in the diseased 
kidney. Future studies in other animal models and clinical 
trials should be possible since there is an existing common 
use of the drug by humans with no knowledge of harmful 
side effects. 
 
mTOR inhibitors 
 
The mammalian target of rapamycin (mTOR) is a 
serine/threonine protein kinase that regulates cell growth, 
cell proliferation, cell motility, cell survival, protein synthesis 
and transcription (Walz, 2006). mTOR has previously been 
identified for its role in proliferation of activated T- 
lymphocytes (Walz, 2006). As a result, Rapamycin has been 
approved by the Food and Drug Administration (FDA) as an 
immunosuppressive drug used after organ transplantation to 
prevent transplant rejection (Shillingford, et. al., 2006). The 
mTOR inhibitor, Rapamycin effectively blocks cyst 
progression, inhibits cyst and kidney growth and prevents 
renal failure (Shillingford, et. al., 2006). These findings 
nurture the hope that therapeutics for ADPKD, since the 
drug has been safely used over extended periods of time in 
humans and inhibits renal failure. Future studies in other 
animal models of PKD and even clinical studies in human 
should prove vital in the search for a cure.  
 
Conclusion  
 
Polycystic kidney disease is characterized by the abnormal 
growth of fluid filled cysts on the kidneys. This cystic growth 
eventually impairs the normal function of the kidney and the 
urinary system. There are many gaps in our understanding 
of this disease such as the mechanism of cyst formation and 
how this process can be regulated. By uncovering the 
normal protein function(s) of PKD1, PKD2, and PKHD1, we 
will be able to determine how the mutated forms of these 
proteins alter the cell cycle. 
PKD1 and PKD2 play important roles in cell 
proliferation. PKD1 acts as a tumor suppressor, induces cdk 
inhibition, decreases cdk 2 activity, and arrests the cell cycle. 
PKD2 is a channel like transmembrane protein that regulates 
ion transport.  PKD2 interacts with Hax-1 and cortactin which 
suggests a possible link between PKD2 and the actin 
cytoskeleton. These findings provide insight as to how the 
disease is initiated and how it progresses throughout the 
kidneys in ADPKD.  
The recessive form of the disease has not been as 
widely studied because the PKHD1 gene was only recently 
discovered. PKHD1 codes for fibrocystin, a transmembrane 
protein, whose function is not completely known. One 
difficulty inhibiting the discovery of ARPKD is that each case 
of the disease has private mutations. 
Without a real cure for PKD, kidney transplant and 
dialysis are the most effective forms of treatment.  Other 
therapies are being considered, such as the CDK inhibitor 
roscovitine.  However, these therapies have only been 
tested on animal models and their effects on human patients 
with PKD can only be hypothesized.  The focus of future 
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therapy research should be on further testing of potential 
drugs, like roscovitine, on PKD in different animal models to 
test whether they are equally effective. This, however, 
cannot be accomplished without first discovering the normal 
function of PKD1, PKD2, and PKHD1 and how these gene 
mutations cause ADPKD and ARPKD. 
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